Heroin-using drivers: Importance of morphine and morphine-6-glucuronide on late clinical impairment

European Journal of Clinical Pharmacology

Volumn 62, Issue 11, 2006, Pages 905-912

  Bachs, Liliana ^a   Høiseth, Gudrun ^a   Skurtveit, Svetlana ^a   Mørland, Jørg ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Heroin; Impairment; Morphine; Morphine 3 glucuronide; Morphine 6 glucuronide; Traffic

Indexed keywords

DIAMORPHINE; MORPHINE; MORPHINE 6 GLUCURONIDE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DATA BASE; DRIVER; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER;

ADULT; AUTOMOBILE DRIVING; COGNITION; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; MORPHINE; MORPHINE DERIVATIVES; NARCOTICS; PSYCHOMOTOR PERFORMANCE; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE DETECTION; TIME FACTORS;

EID: 33750484999     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0195-y     Document Type: Article

References (38)

1. Aasmundstad TA, Ripel A, Bodd E, Bjorneboe A, Morland J (1993) Different biotransformation of morphine in isolated liver cells from guinea pig and rat. Biochem Pharmacol 46:961-968
2. Antonilli L, Semeraro F, Suriano C, Signore L, Nencini P (2003) High levels of morphine-6-glucuronide in street heroin addicts. Psychopharmacology 170:200-204
3. Bachs L, Skurtveit S, Morland J (2003) Codeine and clinical impairment in samples in which morphine is not detected. Eur J Clin Pharmacol 58:785-789
4. Bramness JG, Hilberg TA (2004) Klinisk legeundersøkelse av personer mistenkt for kjøring i påvirket tilstand. En veiledning. Nasjonalt folkehelseinstitutt, Oslo
5. Bramness JG, Skurtveit S, Morland J (2002) Clinical impairment of benzodiazepines-relation between benzodiazepine concentrations and impairment in apprehended drivers. Drug Alcohol Depend 68:131-141
6. Bramness JG, Skurtveit S, Morland J (2003) Testing for benzodiazepine inebriation-relationship between benzodiazepine concentration and simple clinical tests for impairment in a sample of drugged drivers. Eur J Clin Pharmacol 59:593-601
7. Bramness JG, Skurtveit S, Morland J (2004) Impairment due to intake of carisoprodol. Drug Alcohol Depend 74:311-318
8. Bruera E, Macmillan K, Hanson J, MacDonald RN (1989) The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 39:13-16
9. Byas-Smith MG, Chapman SL, Reed B, Cotsonis G (2005) The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain 21:345-352
10. Ceder G, Jones AW (2001) Concentration ratios of morphine to codeine in blood of impaired drivers as evidence of heroin use and not medication with codeine. Clin Chem 47:1980-1984
11. Christophersen AS, Ceder G, Kristinsson J, Lillsunde P, Steentoft A (1999) Drugged driving in the Nordic countries - a comparative study between five countries. Forensic Sci Int 106:173-190
12. Christophersen AS,Morland J (1997)Drugged driving, a review based on the experience in Norway. Drug Alcohol Depend 47:125-135
13. Christophersen AS, Skurtveit S, Grung M, Morland J (2002) Rearrest rates among Norwegian drugged drivers compared with drunken drivers. Drug Alcohol Depend 66:85-92
14. Gjerde H, Christophersen AS, Skuterud B, Klemetsen K, Morland J (1990) Screening for drugs in forensic blood samples using EMIT urine assays. Forensic Sci Int 44:179-185
15. Gustavsen I, Morland J, Bramness JG (2006) Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers. Accid Anal Prev 38:490-495
16. Hausken AM, Skurtveit S, Christophersen AS (2004) Characteristics of drivers testing positive for heroin or ecstasy in Norway. Traffic Inj Prev 5:107-111
17. Ho ST, Wang JJ, Huang JC, Lin MT, Liaw WJ (2002) The magnitude of acute tolerance to morphine analgesia: concentration-dependent or time-dependent? Anesth Analg 95:948-951
18. Horvath G, Kekesi G, Dobos I, Klimscha W, Benedek G (2005) Long-term changes in the antinociceptive potency of morphine or dexmedetomidine after a single treatment. Anesth Analg 101:812-818
19. Jasinski DR, Preston KL (1986) Comparison of intravenously administered methadone, morphine and heroin. Drug Alcohol Depend 17:301-310
20. Kanof PD, Aronson MJ, Ness R, Cochrane KJ, Horvath TB, Handelsman L (1991) Levels of opioid physical dependence in heroin addicts. Drug Alcohol Depend 27:253-262
21. Kerr B, Hill H, Coda B, Calogero M, Chapman CR, Hunt E, Buffington V, Mackie A (1991) Concentration-related effects of morphine on cognition and motor control in human subjects. Neuropsychopharmacology 5:157-166
22. Kilpatrick GJ, Smith TW (2005) Morphine-6-glucuronide: actions and mechanisms. Med Res Rev 25:521-544
23. Kuitunen T (1994) Drug and ethanol effects on the clinical test for drunkenness: single doses of ethanol, hypnotic drugs and antidepressant drugs. Pharmacol Toxicol 75:91-98
24. Liu N, Li B, Wilson FA, Ma Y, Hu X (2005) Gender effect on the right-left discrimination task in a sample of heroin-dependent patients. Psychopharmacology 181:735-740
25. Liu N, Zhou D, Li B, Ma Y, Hu X (2006) Gender related effects of heroin abuse on the simple reaction time task. Addict Behav 31:187-190
26. Lotsch J (2005) Opioid metabolites. J Pain Symptom Manage 29:S10-S24
27. Lotsch J (2005) Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 29:S90-S103
28. Mørland J (2003) Mantenance treatment and car driving. In: Waal H, Haga E (eds) Mantenance treatment of heroin addictionevidence at the crossroads. Cappelen Akademisk Forlag, Oslo
29. Osborne R, Joel S, Trew D, Slevin M (1990) Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 47:12-19
30. Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML (2000) Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther 68:667-676
31. Penson RT, Joel SP, Clark S, Gloyne A, Slevin ML (2001) Limited phase I study of morphine-3-glucuronide. J Pharm Sci 90:1810-1816
32. Rook EJ, van Ree JM, van den BW, Hillebrand MJ, Huitema AD, Hendriks VM, Beijnen JH (2006) Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic Clin Pharmacol Toxicol 98:86-96
33. Shinar D, Schechtman E (2005) Drug identification performance on the basis of observable signs and symptoms. Accid Anal Prev 37:843-851
34. Skurtveit S, Christophersen AS, Grung M, Morland J (2002) Increased mortality among previously apprehended drunken and drugged drivers. Drug Alcohol Depend 68:143-150
35. Smith MT, Watt JA, Cramond T (1990) Morphine-3-glucuronide - a potent antagonist of morphine analgesia. Life Sci 47:579-585
36. Vainio A, Ollila J, Matikainen E, Rosenberg P, Kalso E (1995) Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 346:667-670
37. Zacny JP (1995) A review of the effects of opioids on psychomotor and cognitive functioning in humans. Exp Clin Psychopharmacol 3:432-466
38. Zacny JP, Lichtor JL, Flemming D, Coalson DW, Thompson WK (1994) A dose-response analysis of the subjective, psychomotor and physiological effects of intravenous morphine in healthy volunteers. J Pharmacol Exp Ther 268:1-9